Phase 2 N=214 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
Asthma
Primary: Time to First Asthma Worsening During the Planned 24 Week Treatment Period — 40.00; 85.50 Days — p=0.0255
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
Respiratory Distress Syndrome, Adult
Primary: Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion — 0; 0 Participants
Phase 3 N=88 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
Hemophilia A
Primary: Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age — 0.3 treated bleed rate per year
Phase 4 N=88 Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
Depression
Primary: Response as Assessed by Participants' Change in Depression Rating — 17; 11; 1; 9 Participants
Phase 2 N=151 Selonsertib in Adults With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214
Phase 4 N=283 Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Pulmonary Disease, Chronic Obstructive
Primary: Percentage Change From Baseline in Bone Mineral Density (BMD) Measured at Total Hip — 0.18; -0.27; 0.37; 0.31 Percentage change
Phase 2 N=123 Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1
Cocaine Dependence
Primary: Number of Cocaine Non-use Days — 10.1; 17.1; 9.3; 14.1 Number of Days
Phase 2 N=118 ToRsemide for pOstpartum HYpertension
Preeclampsia
Primary: Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg — 26; 34 Participants
N/A N=255 Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM
Diabetes Mellitus, Type 2 · Diabetes Mellitus, Adult-Onset · Diabetes Mellitus, Non-Insulin-Dependent
Primary: Hemoglobin A1c (HbA1c) at 12 Months Post Randomization — 9.3; 9.2; 9.2; 9.5 percentage of glycosylated hemoglobin
Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…
Phase 2 N=56 Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin
Physical Activity
Primary: Mitochondrial Function — 7.1; 43.2; 15.6; 13.8 percent change in pmol/s/mg tissue
Phase 3 N=350 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Percentage of Participants Responded for Assessment of Spondyloarthritis International Society 20 Criteria (ASAS20) at 16 Weeks — 60.5; 65.5; 49.1 percentage of…
N/A N=32 Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 2.4 events per hour
Phase 2 N=313 Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator
Ventricular Arrhythmia
Primary: Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24…
Phase 3 N=1,224 Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
Hepatitis C
Primary: Number of Participants Achieving Responder Status at 24 Weeks of Treatment — 80; 87; 90; 59 Participants — p=0.078